Details : Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product URO-902 (hMaxi-K), showed clinically relevant improvement in the common symptoms of overactive bladder (OAB) compared to placebo.
Brand Name : URO-902
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 13, 2022
Details : Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder and urge urinary incontinence will be featured in a late-breaker presentation during plenary session.
Brand Name : URO-902
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 13, 2022
Details : URO-902 showed a clinically meaningful and statistically significant effect on a number of relevant outcome measures in OAB including number of micturitions, urgency episodes, and quality of life indicators compared to placebo, 12 weeks post-administrati...
Brand Name : URO-902
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 07, 2022
LOOKING FOR A SUPPLIER?
Reset All
